



# Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Brief report

## Bacteremia due to *Leuconostoc* species: A 13-year single-center case series



José María Caso<sup>a,\*</sup>, Raúl Recio<sup>b</sup>, María Ruiz-Ruigómez<sup>c</sup>,  
María Ángeles Orellana<sup>b</sup>, Mario Fernández-Ruiz<sup>c,d,e</sup>

<sup>a</sup> Department of Internal Medicine, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), Madrid, Spain

<sup>b</sup> Department of Microbiology, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), Madrid, Spain

<sup>c</sup> Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), Madrid, Spain

<sup>d</sup> Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain

<sup>e</sup> Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Spain

### ARTICLE INFO

#### Article history:

Received 17 October 2022

Accepted 10 January 2023

Available online 21 February 2023

#### Keywords:

*Leuconostoc* spp

Bacteremia

Infection

Treatment

Outcome

### ABSTRACT

**Introduction:** *Leuconostoc* spp. are facultatively anaerobic Gram-positive cocci involved in cases of hospital-acquired bacteremia, mainly in immunocompromised hosts. The available data is scarce due to its uncommon presentation.

**Methods:** We describe all the episodes of *Leuconostoc* spp. bacteremia in a third level hospital in a 13-year period (2008–2021).

**Results:** Four cases of clinically relevant bacteremia were detected. All cases were categorized as catheter-related. The following risk factors were found: previous glycopeptide therapy (75%), use of parenteral nutrition (100%) and cancer (75%). All isolates showed susceptibility to beta-lactams. Catheter removal was performed and wide spectrum antimicrobials were administered, with clinical response in all cases except one.

**Discussion:** Apart from cancer and glycopeptide exposure, disruption of skin barrier and gastrointestinal conditions were identified as risk factors, as it was concordantly underlined in other case series. Susceptibility to beta-lactams is usually maintained. Catheter removal and administration of an active antibacterial therapy seem to be the best approach for *Leuconostoc* spp. catheter-related bacteremia.

© 2023 Sociedad Española de

Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

## Bacteriemia por *Leuconostoc* spp.: serie de casos en un hospital de tercer nivel a lo largo de 13 años

### RESUMEN

**Introducción:** Los microorganismos del género *Leuconostoc* son cocos grampositivos anaerobios facultativos, involucrados en casos de bacteriemia en pacientes hospitalizados, especialmente con factores de inmunosupresión. La literatura disponible es escasa por su baja frecuencia.

**Métodos:** Describimos todos los episodios de bacteriemia por *Leuconostoc* spp. en un hospital de tercer nivel en un periodo de 13 años (2008–2021).

**Resultados:** Se detectaron 4 aislamientos clínicamente significativos. Todos ellos fueron categorizados como bacteriemia relacionada con catéter. Se identificaron como factores de riesgo: la exposición previa a glucopéptidos (75%), nutrición parenteral (100%) y cáncer (75%). Todos los aislamientos presentaron sensibilidad a betalactámicos. Se procedió a retirada del catéter y se administraron antimicrobianos de amplio espectro con buena respuesta clínica, salvo en un caso.

#### Palabras clave:

*Leuconostoc* spp

Bacteriemia

Infección

Tratamiento

Desenlace

\* Corresponding author.

E-mail address: [jmcasolaviana@gmail.com](mailto:jmcasolaviana@gmail.com) (J.M. Caso).

**Discusión:** Además del cáncer y la exposición a glucopéptidos, la disrupción de la barrera cutánea y las enfermedades gastrointestinales se identificaron como factores de riesgo, al igual que en otras series. La sensibilidad a betalactámicos suele mantenerse. La retirada del catéter y el uso de terapia antibiótica activa parece ser la mejor alternativa terapéutica para la bacteriemia relacionada con catéter por *Leuconostoc* spp.

© 2023 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

*Leuconostoc* spp. (order *Lactobacillales*) are catalase-negative, alpha-hemolytic, facultatively anaerobic Gram-positive cocci usually arranged in pairs or chains and often found in fermenting vegetables, milk, dairy products, wines and meats. These bacteria exhibit high-level intrinsic resistance to glycopeptides due to the presence of peptidoglycan precursors of the cell wall terminating in D-alanyl-D-lactate rather than D-alanyl-D-alanine.<sup>1</sup> Although once considered as non-pathogenic, since 1985 *Leuconostoc* spp. has been occasionally reported to be involved in hospital-acquired infections among immunocompromised patients<sup>2–4</sup> or low birth weight premature neonates with underlying gastrointestinal conditions.<sup>5,6</sup> One case of bacteremia was reported in an immunocompetent adult with ileum perforation.<sup>7</sup> However, available data regarding risk factors, therapeutic approaches and outcomes is limited. We aimed to describe clinical features and outcome of all cases of *Leuconostoc* spp. bacteremia in our institution.

## Methods

We reviewed all cases of documented, clinically significant *Leuconostoc* spp. bacteremia diagnosed over a 13-year period (January 2008–December 2021) in a 1300-bed tertiary-care center in Madrid (Spain) with a reference population of 451,000 inhabitants in 2020. Cases were identified through the computerized database of the Department of Microbiology and defined by the isolation of *Leuconostoc* spp. in one or more blood cultures in the presence of symptoms and signs of systemic infection. Blood samples were processed using the BacT/Alert 3D® and BacT/Alert VIRTUO® systems (bioMérieux, Marcy-l'Étoile, France). All blood culture bottles were incubated for 5 days before being considered as negative. All isolates were identified with the VITEK® 2 system (bioMérieux) and, since 2014, with the MALDI-TOF MS Biotyper system (Bruker Daltonics Inc., Bremen, Germany). Antimicrobial susceptibility to penicillin, ceftriaxone, levofloxacin, vancomycin and cotrimoxazole was tested by the agar disk-diffusion method using Mueller-Hilton agar supplemented with sheep blood at 5% (bioMérieux) in accordance with the Clinical Laboratory Standards Institute (M45, CLSI). Since breakpoints of many antimicrobials are not available for *Leuconostoc* spp. in CLSI documents, we applied the *Streptococcus pneumoniae* breakpoints described in the 2006, 2010 and 2016 CLSI editions.

## Results

We identified eight episodes of positive blood cultures for *Leuconostoc* spp. during the study period. Four were considered contaminants due the positivity of a single set of at least two drawn at the same time. Table 1 details the clinical and microbiological characteristics of the remaining four cases of true *Leuconostoc* spp. bacteremia. The clinical presentation fulfilled the definition of sepsis and included fever and elevation of acute phase reactants, although none of the episodes progressed to septic shock.

Three of the patients exhibited at least one condition leading to immune compromise, including cancer (three cases), neutropenia (i.e. absolute neutrophil count  $< 0.50 \times 10^9$  cells/L) or corticosteroid therapy (two cases each). The diagnosis of acute myeloid leukemia was present in two patients. The four episodes were considered as likely related to the intravascular catheter due to the absence of an alternative origin of bacteremia and the rapid clearance following catheter withdrawal. Follow-up blood cultures were obtained and were sterile in all four cases. Polymicrobial infection was present in one case in which *Staphylococcus capitis* was concomitantly identified in blood cultures, a circumstance that would support the diagnosis of catheter-related bacteremia. Three of our patients had received vancomycin or teicoplanin within the 90 days preceding the onset of bacteremia. All isolates in our series showed susceptibility to penicillin, ceftriaxone and levofloxacin, whereas cotrimoxazole resistance was documented in one single case. All isolates were susceptible to beta-lactams, although the therapeutic regimens used were quite heterogeneous and included linezolid, levofloxacin, clindamycin and tigecycline. Catheter removal was performed in all four cases.

## Discussion

Previous studies have documented the increased susceptibility to *Leuconostoc* spp. bacteremia among patients with cancer, in which prolonged hospitalization periods and exposure to broad-spectrum antibiotics may play a role.<sup>2,8</sup> Four out of nine cancer patients in a previous series reported also had a hematological malignancy, mainly acute lymphoblastic leukemia.<sup>3</sup> In addition to the impairment of host immune response, the disruption of skin barrier function due to the presence of indwelling vascular catheters is another major contributor to *Leuconostoc* spp. infection.<sup>2,4</sup> Parenteral nutrition was also identified as a risk factor in a case-control study performed in the setting of a hospital outbreak of *L. mesenteroides* subsp. *mesenteroides* bacteremia.<sup>2</sup> The predominance of the vascular catheter as the presumed source of infection is concordant with the results reported by a recent Taiwanese cohort comprising 20 episodes, although none of the nine central venous catheter (CVC) tips cultured yielded Gram-positive cocci.<sup>4</sup> Bacterial translocation from the gastrointestinal tract has been also proposed as a potential source among patients with malignancies.<sup>3</sup> We should point out as a limitation the absence of a definite diagnosis of catheter-related bloodstream infection. CVC tip culture was negative in almost all cases of our series, except case #4. In addition, one single set of blood culture was obtained in each case, therefore differential time to positivity was not possible to perform. Antibiotic exposure in the preceding weeks has been identified as a frequent risk factor in previous studies, with glycopeptides and broad-spectrum beta-lactams being the agents most commonly reported.<sup>2–4</sup>

Misidentification of *Leuconostoc* spp. isolates is not uncommon since colonies may resemble *viridans* group streptococci or enterococci when cultured on sheep blood agar.<sup>9</sup> The presence of alpha-hemolytic, catalase-negative Gram-positive cocci with high-level vancomycin resistance and negative for pyrrolidonyl

**Table 1**  
Clinical and microbiological characteristics, therapeutic regimens and outcome of four cases of *Leuconostoc* spp. bacteremia.

Case	Date	Gender/age	Underlying condition	Additional risk factors	Indwelling vascular catheters	Exposure to glycopeptides in the previous 90 days	Isolated species	Presumed source	Catheter removal (days after bacteremia)	Catheter tip culture	Antibiotic therapy	Length of therapy	Outcome
1	2008	F/6 months	Acute myeloid leukemia	Neutropenia, CVC, PVC corticosteroid therapy		Yes	<i>Leuconostoc</i> spp.	Intravascular catheter	Yes (0 days)	Sterile	Meropenem	36 days	Clinical response, death due to unrelated causes
2	2010	M/63 years	Hypopharynx epidermoid carcinoma	Diabetes mellitus	PVC	No	<i>Leuconostoc mesenteroides</i>	Intravascular catheter	Yes (0 days)	No	Amoxicillin/clavulanate	3 days	Death due to unrelated causes
3	2013	M/45 years	Acute myeloid leukemia	Neutropenia, CVC, PVC corticosteroid therapy		Yes	<i>Leuconostoc</i> spp.	Intravascular catheter	Yes (3 days)	Sterile	Levofloxacin, 14 days clindamycin		Clinical and microbiological response
4	2018	F/72 years	Acute pancreatitis	None	CVC, PVC	Yes	<i>Leuconostoc lactis</i>	Intravascular catheter	Yes (3 days)	<i>Leuconostoc lactis</i>	Tigecycline	14 days	Clinical and microbiological response

CVC: central venous catheter; F: female; M: male; PVC: peripheral venous catheter.

aminopeptidase (PYR) and L-leucine amino peptidase (LAP) production serve as criteria for genus-level differentiation.<sup>9</sup> Initial misidentification with *Weissella* spp. was frequent due to its phenotypical and biochemical similarities, but currently definite identification can be achieved with MALDI-TOF.<sup>10,11</sup>

As exemplified by this and other series,<sup>4</sup> *Leuconostoc* spp. isolates were susceptible to beta-lactams. The optimal duration of therapy is not well established, although the criteria used for catheter-related bacteremia due to coagulase-negative staphylococci would be applicable. The prolonged course of meropenem therapy in case #1 may be explained by the lack of clinical stability and the uncertainty on the focus of infection. The successful use of tygecycline has been recently reported in a neutropenic patient.<sup>12</sup> In line with most<sup>3,13</sup> but not all previous series,<sup>4</sup> outcomes were overall good, with no cases of persistent bacteremia or attributable mortality.

In conclusion, bacteremia due to *Leuconostoc* spp. is an uncommon but expected condition in patients with predisposing factors such as immune impairment, indwelling vascular catheters or previous exposure to vancomycin. Its relevance lies in the appropriate choice of therapy, given the difficulty to differentiate *Leuconostoc* spp. isolates from other Gram-positive cocci that are usually susceptible to glycopeptides. Once genus identification is confirmed, infection focus should be removed and antimicrobial treatment must be verified.

### Funding sources

R.R. hold a research training contract “Río Hortega” (CM19/00229) and M.F.R. a research contract “Miguel Servet” (CP 18/00073), both from the Spanish Ministry of Science, Instituto de Salud Carlos III.

### Conflict of interest

All authors: The authors declare that they have no conflict of interest.

### References

- Nelson RR. Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. *J Hosp*

- Infect. 1999;42:275–82. <http://dx.doi.org/10.1053/jhin.1998.0605>. PMID: 10467540.
- Bou G, Luis Saleta J, Sáez Nieto JA, Tomás M, Valdezate S, Sousa D, et al. Nosocomial outbreaks caused by *Leuconostoc mesenteroides* subsp. *mesenteroides*. *Emerg Infect Dis*. 2008;14:968–71. <http://dx.doi.org/10.3201/eid1406.071095>. PMID: 18507917; PMCID: PMC2600284.
- Sonia I, Cuervo M, Cortés LJ, Rodríguez RE, Hormaza AN, Vargas SE. *Leuconostoc* spp. in cancer patients: a descriptive study. *Rev Chilena Infectol*. 2008;25:184–8. Epub 2008 Jun 24.
- Lee MR, Huang YT, Lee PI, Liao CH, Lai CC, Lee LN, et al. Healthcare-associated bacteraemia caused by *Leuconostoc* species at a university hospital in Taiwan between 1995 and 2008. *J Hosp Infect*. 2011;78:45–9. <http://dx.doi.org/10.1016/j.jhin.2010.11.014>. Epub 2011 Jan 26. PMID: 21269734.
- Janow G, Lambert B, Scheiner M, Rosen O, Goldman DL, Soghier L. *Leuconostoc* septicemia in a preterm neonate on vancomycin therapy: case report and literature review. *Am J Perinatol*. 2009;26:89–91. <http://dx.doi.org/10.1055/s-0028-1103025>. Epub 2008 Nov 21. PMID: 19031357.
- Yossuck P, Miller-Canfield P, Moffett K, Graeber J. *Leuconostoc* spp sepsis in an extremely low birth weight infant: a case report and review of the literature. *W V Med J*. 2009;105:24–7. PMID: 19806867.
- Meneguetti MG, Gaspar GG, Laus AM, Basile-Filho A, Bellissimo-Rodrigues F, Auxiliadora-Martins M. Bacteremia by *Leuconostoc mesenteroides* in an immunocompetent patient with chronic Chagas disease: a case report. *BMC Infect Dis*. 2018;18:547. <http://dx.doi.org/10.1186/s12879-018-3452-7>. PMID: 30390634.
- Ino K, Nakase K, Suzuki K, Nakamura A, Fujieda A, Katayama N. Bacteremia due to *Leuconostoc pseudomesenteroides* in a patient with acute lymphoblastic leukemia: case report and review of the literature. *Case Rep Hematol*. 2016;2016:7648628. <http://dx.doi.org/10.1155/2016/7648628>. Epub 2016 Aug 22. PMID: 27635268.
- Facklam R, Elliott JA. Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. *Clin Microbiol Rev*. 1995;8:479–89. <http://dx.doi.org/10.1128/CMR.8.4.479>. PMID: 8665466.
- Kamboj K, Vasquez A, Balada-Llasat JM. Identification and significance of *Weissella* species infections. *Front Microbiol*. 2015;6:1204. <http://dx.doi.org/10.3389/fmicb.2015.01204>. PMID: 26583007.
- Gantzias C, Lappa IK, Aerts M, Georgalaki M, Manolopoulou E, Papadimitriou K, et al. MALDI-TOF MS profiling of non-starter lactic acid bacteria from artisanal cheeses of the Greek island of Naxos. *Int J Food Microbiol*. 2020;323:108586. <http://dx.doi.org/10.1016/j.ijfoodmicro.2020.108586>. Epub 2020 Mar 9. PMID: 32199192.
- Patel T, Molloy A, Smith R, Balakrishnan I. Successful treatment of *Leuconostoc* bacteremia in a neutropenic patient with tigecycline. *Infect Dis Rep*. 2012;4:e31. <http://dx.doi.org/10.4081/idr.2012.e31>. PMID: 24470945.
- Handwerker S, Horowitz H, Coburn K, Kolokathis A, Wormser GP. Infection due to *Leuconostoc* species: six cases and review. *Rev Infect Dis*. 1990;12:602–10. <http://dx.doi.org/10.1093/clinids/12.4.602>. PMID: 2201065.